{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"ELOQUENT - 2","nct_id":"NCT01239797","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=eloquent-2-nct01239797. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ELOQUENT - 2","arms":[{"description":null,"label":"Lenalidomide + Dexamethasone","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"Lenalidomide + Dexamethasone +Elotuzumab","type":"EXPERIMENTAL"}],"collaborators":["AbbVie"],"completion_date":{"date":"2021-04-21","type":"ACTUAL"},"conditions":["Lymphoma","Multiple Myeloma"],"enrollment":{"count":646,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Lenalidomide","otherNames":["Revlimid®"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"],"type":"DRUG"},{"name":"Dexamethasone (Oral)","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"],"type":"DRUG"},{"name":"Dexamethasone (IV)","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"],"type":"DRUG"},{"name":"Elotuzumab (BMS-901608; HuLuc63)","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2022-06-01","lead_sponsor":"Bristol-Myers Squibb","official_title":"Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2014-09-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Median Progression Free Survival (PFS)","timeFrame":"From randomization up to 326 events (up to approximately 38 months)"},{"measure":"Objective Response Rate (ORR)","timeFrame":"From randomization up to approximately 38 months"}],"references":[{"citation":"Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 Oct 15;124(20):4032-4043. doi: 10.1002/cncr.31680. Epub 2018 Sep 11.","pmid":"30204239","type":"DERIVED"},{"citation":"Passey C, Mora J, Dodge R, Gibiansky L, Sheng J, Roy A, Bello A, Gupta M. An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab. AAPS J. 2017 Mar;19(2):557-567. doi: 10.1208/s12248-016-0033-9. Epub 2017 Jan 9.","pmid":"28070715","type":"DERIVED"},{"citation":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.","pmid":"26035255","type":"DERIVED"}],"start_date":{"date":"2011-06-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT01239797"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/eloquent-2-nct01239797"}